Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Change in Cash (2016 - 2025)

Editas Medicine (EDIT) has disclosed Change in Cash for 11 consecutive years, with $25.9 million as the latest value for Q3 2025.

  • Quarterly Change in Cash fell 17.5% to $25.9 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $68.6 million through Sep 2025, up 416.09% year-over-year, with the annual reading at $7.9 million for FY2024, 144.15% up from the prior year.
  • Change in Cash for Q3 2025 was $25.9 million at Editas Medicine, up from -$150000.0 in the prior quarter.
  • The five-year high for Change in Cash was $215.2 million in Q1 2021, with the low at -$138.3 million in Q3 2023.
  • Average Change in Cash over 5 years is $1.3 million, with a median of -$150000.0 recorded in 2025.
  • The sharpest move saw Change in Cash skyrocketed 4804.61% in 2021, then crashed 434.79% in 2023.
  • Over 5 years, Change in Cash stood at -$56.4 million in 2021, then fell by 22.74% to -$69.2 million in 2022, then soared by 159.43% to $41.1 million in 2023, then dropped by 13.15% to $35.7 million in 2024, then dropped by 27.47% to $25.9 million in 2025.
  • According to Business Quant data, Change in Cash over the past three periods came in at $25.9 million, -$150000.0, and $7.2 million for Q3 2025, Q2 2025, and Q1 2025 respectively.